The ASGR1 Knockout SK-OV-3 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population derived from SK-OV-3 human ovarian adenocarcinoma cells, with targeted disruption of the ASGR1 gene encoding the asialoglycoprotein receptor major subunit. This heterogeneous pool harbors diverse loss-of-function mutations at the ASGR1 locus, offering a robust loss-of-function model while minimizing clonal artifacts. Ideal for glycobiology and oncology research, this polyclonal format provides a population-level readout of ASGR1-dependent processes.
SK-OV-3 is an epithelial ovarian cancer cell line originally isolated from ascitic fluid of a patient with ovarian serous cystadenocarcinoma. Widely used to study metastasis, drug resistance, and tumor biology, these cells retain molecular hallmarks of high-grade serous carcinoma. Their epithelial origin and relevance to ovarian cancer make them a suitable host for investigating glycoprotein metabolic pathways in a non-hepatic oncogenic milieu.
ASGR1 encodes the major subunit of the asialoglycoprotein receptor, which hetero-oligomerizes with ASGR2 to recognize desialylated glycoproteins via terminal galactose or GalNAc residues. Ligand binding activates clathrin-dependent endocytosis mediated by the AP-2 adaptor and dynamin, directing cargo through Rab5+ early endosomes to lysosomes for degradation. Its transcription is driven by HNF4A, C/EBP alpha, and FOXA2, embedding ASGR1 within hepatocyte nuclear factor networks. The receptor??s function is calcium-dependent and modulated by ligands like asialo-orosomucoid; downstream, it ensures efficient glycoprotein clearance and, in some contexts, contributes to regulated exocytosis.
Disrupting ASGR1 in SK-OV-3 cells provides a unique model to study glycoprotein turnover in ovarian cancer, where altered glycosylation patterns promote metastasis and immune evasion. The knockout uncouples ASGR1-mediated endocytosis from other trafficking pathways, enabling investigation of desialylated glycoprotein accumulation and its tumorigenic consequences. This system is valuable for testing ASGR1-targeted drug delivery and for probing receptor biology in a non-hepatic environment that possesses the necessary endocytic machinery. Additionally, it allows exploration of ectopic ASGR1 function and its interplay with ovarian cancer cell signaling.
Applications of this knockout product extend across biochemical and cell-based assays, including ligand-binding experiments with asialo-orosomucoid, immunofluorescence visualization of clathrin-mediated internalization, and flow cytometry to confirm surface ASGR1 depletion. The polyclonal population is suitable for co-immunoprecipitation studies to assess ASGR2 complex integrity and for endocytosis assays with fluorescent glycoprotein probes. Validation by RT-qPCR and western blotting ensures loss of ASGR1 expression, while functional assays can investigate alterations in glycoprotein catabolism and downstream effects on ovarian cancer drug sensitivity. For further details, technical assistance, or custom requests, please reach out to Ascent Research.
